Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Top Cited Papers
- 9 November 2011
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 13 (1), 100-110
- https://doi.org/10.1016/s1470-2045(11)70287-x
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protectionVaccine, 2011
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide studyThe Lancet Oncology, 2010
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenThe Lancet, 2009
- Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implicationsProtein Science, 2009
- Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinantsInternational Journal of Cancer, 2009
- A review of human carcinogens—Part B: biological agentsThe Lancet Oncology, 2009
- Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa RicaVaccine, 2008
- Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysisBritish Journal of Cancer, 2003
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- The Rising Incidence of Adenocarcinoma Relative to Squamous Cell Carcinoma of the Uterine Cervix in the United States—A 24-Year Population-Based StudyGynecologic Oncology, 2000